CTRI/2021/04/032528已完成3 期
Role of NK-1 receptor antagonist for prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC): An Investigator-initiated, Multicenter, Double blind, Randomized, Placebo controlled, Superiority trial
CI AIIMS0 个研究点目标入组 250 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a. Diagnosis of malignancy
- •b. No prior chemotherapy and radiation therapy (RT)
- •c. Age of 18 years or more, up to 70 years
- •d. ECOG Performance status (0-2)
- •e. Complete hemogram (ANC >=1000/m3, TLC >=3000/m3, Platelets >= 1,00,000/m3), Creatinine (<= 2 mg/dl), SGOT / SGPT (<= 3 X ULN, Bilirubin <2.0 mg/dl)
- •f. First cycle of highly emetogenic chemotherapy defined as
- •1. Cisplatin at dose >=70mg/m2 with or without other agents
- •2. Single agent Anthracycline (Doxorubicin >= 60mg/m2, Epirubicin >= 90mg/m2)
- •3. AC (Doxorubicin >= 60mg/m2, Epirubicin >= 90mg/m2 + Cyclophosphamide >=
- •4. Dacarbazine based therapy (ABVD)
- •g. Willing to give written informed consent for the study participation
- •h. Able to read and write in English or Hindi
排除标准
- •a. Patient receiving concurrent quinolone, amifostine, warfarin, OCP, psychiatric drugs, Benzodiazepines, Anti-convulsant drugs, strong or moderate CYP3A4 inhibitors (diltiazem, Ketoconazole), strong CYP3A4 inducers (rifampicin), pimozide, cisapride, terfenadine, astemizole, CYP1A2 inhibitors (ciprofloxacin, fluvoxamine)
- •b. History of chronic alcoholism
- •c. Hypersensitivity to any of the drugs used in the study {Olanzapine, NK-1 antagonist (Fosaprepitant), 5-HT3 antagonist â?? Ondansetron}
- •d. On systemic steroids, active smoker
- •e. History of any uncontrolled systemic disease including hypertension, thyroid, CNS, renal, CHF and MI in last 6 months and requiring hemodialysis, psychiatric disorder
- •f. Symptomatic Brain metastasis / Carcinomatous Meningitis
- •g. History of nausea and vomiting in 24 hours prior to first dose of chemotherapy
- •i. Use of anti-emetic drugs (5-HT3 Antagonist) in last 48 hours
- •j. Ascites requiring therapeutic paracentesis in last 2 weeks, Intestinal obstruction
- •k. Started on opioids in last 48 hours
- •l. Female who are pregnant, lactating
- •m. Diabetic patient on oral hypoglycemic drugs or Insulin
研究者
相似试验
招募中
不适用
Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer.Advanced gastric cancerJPRN-UMIN000011962Gastroenterologic Surgery, Kanazawa University55
招募中
2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.hematologic malignanciesJPRN-UMIN000006690Kagoshima University Hospital, division of Hematology and Immunology40
招募中
不适用
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.JPRN-UMIN000005317Department of gynecology, Fukuoka University Hospital60
招募中
1 期
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial.Study 2: Patients on the waiting list for kidney transplantation.Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantationCTIS2023-506436-33-00Bellvitge University Hospital20
招募中
1 期
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial.Study 1: Immediate Kidney Transplant RecipientsPreventive treatment of post-kidney transplant diabetesCTIS2023-506437-29-00Bellvitge University Hospital128
